Inflazyme pulmonary, neurology news

IZP will discontinue R&D on its Mirococept product and Prodaptin technology platform and will now focus on developing IPL512,602 and IPL455,903 for asthma and cognitive dysfunction, respectively. IZP is not reducing headcount.

IPL455,903, a phosphodiesterase 4 ( PDE-4) inhibitor, is partnered with Helicon Therapeutics Inc. (Uniondale, N.Y.) and is in Phase I trials. Helicon plans to start a Phase II trial early next year. IZP has an option to reacquire 50% of IPL455,903 until Phase II testing is complete. ...